

We are the only PARKINSON'S FOUNDATION CENTER OF EXCELLENCE in the region with comprehensive care including doctors specialized in the diagnostics, treatment, research, and education of Parkinson's disease. We have a large multi-disciplinary team including healthcare professionals specialized in Parkinson's disease in the areas of psychology, speech, physical therapy, occupational therapy, dietetics, social work, pharmacy, neuropsychology, and neurosurgery, including a large deep brain stimulation program.

## Parkinson's Disease Symposium, Saturday August 13, 2022!

We are excited to announce that our Parkinson's Disease Symposium will be live this year at the Overland Park Marriott on August 13, 2022! Doors open at 8:00am for exhibits, and presentations will begin at 9:00am. The presentations include: **What Is PD: Symptoms, Causes and Treatments**, Kelvin Au, MD, KUMC; **Surgical Treatment for PD: When Is It An Option & Who Is A Candidate?** Vibhash Sharma, MD, KUMC; **Diet and PD: A Balanced Diet for Healthy Weight and Understanding Dietary Supplements**, Swarna Mandali, PhD, RD, CSSD, KUMC; **Is the End of Parkinson's Disease Near? The Role of Genes and Future Treatment Options**, Stuart Isaacson, MD, PD Center Boca Raton, FL; **Your Questions, Our Answers**, Rajesh Pahwa, MD, KUMC & Stuart Isaacson, Boca Raton. The program is free but registration is requested. Light snacks, coffee, and water will be provided. Parking is free outside the Overland Park Marriott. To register email [pdetcenter@kumc.edu](mailto:pdetcenter@kumc.edu) or call 913-588-0013 or **CLICK HERE**



**RAJESH PAHWA, MD**

Laverne and Joyce Rider  
Professor of Neurology  
Director, Parkinson's  
Disease and Movement  
Disorder Center



**KELLY LYONS, PhD**

Research Professor  
of Neurology  
Director, Research and  
Education, Parkinson's Disease  
and Movement Disorder Center

## TREMOR CORNER

ET Studies Ongoing!

**JZP385** – ET with moderate to severe arm/hand tremor. Cannot be taking ET medications

**PRAX-944** – ET for at least 3 years with at least moderate arm/hand tremor. Cannot be taking primidone.

**SAGE-324** – ET for at least 3 years with at least moderate arm/hand tremor. Cannot be taking other medications for ET.

If you are interested in participating in a research study or would like more information, please email [pdetcenter@kumc.edu](mailto:pdetcenter@kumc.edu) or call 913-588-7159.

## CLINICAL STUDIES RECRUITING

We have multiple ongoing and upcoming studies for PD. We are currently enrolling for the following studies:

- Newly diagnosed PD patients - Possible disease slowing**
  - UCB0599** – PD patients diagnosed < 2 yrs, never taken PD medications
  - K0706** – PD patients diagnosed < 3 years and not taking any PD medications
  - CVL-751** – PD patients diagnosed for < 3 years and taking no PD medications except for an MAO-B inhibitor
- Stable PD patients**
  - PADOVA** – PD patients taking only an MAO-B inhibitor OR levodopa diagnosed within the last 3 years
- PD patients experiencing OFF time (poor control of symptoms) during waking hours**
  - AMDC-009-103** – PD patients experiencing OFF time, on demand inhalation therapy for OFF episodes
  - CVL-751** – PD patients with at least 2.5 hours of OFF time per day
- PD patients experiencing troublesome dyskinesia (wiggling movements from levodopa)**
  - BK-JM-201** – PD patients with at least 1.5 hours of troublesome dyskinesia daily and not taking or willing to stop amantadine
- PD Generation Mapping the Future of Parkinson's Disease** – Testing for 7 genes that have been shown to increase the risk of developing Parkinson's disease. Anyone diagnosed with Parkinson's disease in our region can participate.
- The Parkinson's Progression Markers Initiative (PPMI)**
  - Parkinson's Disease cohort (PD diagnosed within the last 2 years, not on or expected to need meds for 6 months)
  - Prodromal cohort (1<sup>st</sup> degree relative with PD, REM sleep behavior disorder (RBD), or known genetic variants; 60+ years of age),
  - Healthy Controls (30+ years of age).

If you are interested or have patients who are interested in learning more about any of these research studies, please contact [PDETCenter@kumc.edu](mailto:PDETCenter@kumc.edu)

## RESEARCH HIGHLIGHT

### Efficacy of Inhaled Apomorphine

Apomorphine is a dopamine agonist that is approved for ON-Demand therapy in patients with PD. ON-Demand therapies are used as needed upon awakening or throughout the day, when OFF episodes occur. These therapies are currently available as inhaled levodopa and as a subcutaneous injection or sublingual (under the tongue) strip of apomorphine.

A recent study evaluated the safety and efficacy of an investigational inhaled apomorphine in PD patients. Twenty-four patients with OFF periods received inhaled apomorphine (Staccato apomorphine). Inhaled apomorphine was rapidly absorbed and improved PD motor symptoms within 10 minutes. The most common side effects were throat irritation, yawning, nausea, low blood pressure, and sleepiness.

Inhaled apomorphine studies are ongoing at KUMC, please email [pdetcenter@kumc.edu](mailto:pdetcenter@kumc.edu) or call 913-588-0013 if interested.

## Helen Gold 5K/10K, WALK/RUN FOR PARKINSON'S DISEASE, BACK THIS YEAR!

September 10th, 2022, 8:00 a.m., La Paloma Plaza,  
119th & Glenwood, Overland Park, KS.

Please join us to walk, run, volunteer, sponsor, or just come to enjoy the morning! All funds raised support PD research at KUMC!

**Visit [Helengold5k.com](http://Helengold5k.com) to sign up!**

Visit our website: [KUMC.EDU/PARKINSON](http://KUMC.EDU/PARKINSON)